Adalimumab: Nursing Guide, TNF-Inhibitor Safety & Infection Screening
Adalimumab is a tumor necrosis factor (TNF) blocker used for autoimmune and inflammatory conditions — where nurses must confirm infection screening, avoid starting therapy during active infection, teach safe subcutaneous technique, and escalate fever, TB symptoms, or hepatitis B reactivation signs according to facility policy.
Contents
Quick Facts
Key Takeaway
The main nursing priority with adalimumab is infection safety before the first dose and at every visit: confirm latent tuberculosis screening, hepatitis B status when at risk, and that the patient has no active infection. Do not administer during untreated active infection — escalate new fever, cough, weight loss, or jaundice promptly and document injection site, lot, and patient teaching.
- Confirm latent TB screening completed and reviewed before first dose
- Verify hepatitis B status in at-risk patients per prescriber order
- Assess for active infection — do not start or give dose during active infection per FDA label
- Review live-vaccine history; live vaccines should be avoided with adalimumab
- Confirm correct patient, dose, device, and expiration date on pen or syringe
- Inspect medication for particulate matter and discoloration if using vial per label
- Verify injection site is not infected, bruised, or scarred; plan site rotation
- Ensure patient or caregiver trained in subcutaneous technique when self-administering
What is Adalimumab?
Adalimumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds tumor necrosis factor (TNF-alpha), reducing inflammatory activity in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection using prefilled pens, prefilled syringes, or institutional vials.
Overview
Nurses encounter adalimumab in rheumatology, gastroenterology, dermatology, and outpatient infusion or injection clinics. Brand names include HUMIRA and multiple FDA-approved biosimilars; nursing principles for screening, infection surveillance, and injection safety apply across products unless the specific label differs.
Because TNF blockade increases risk of serious infections — including tuberculosis reactivation and invasive fungal disease — nursing care extends beyond giving an injection. Screening must precede the first dose, patients need ongoing infection education, and any new systemic illness while on therapy requires prompt clinical review rather than automatic continuation.
Before the first adalimumab dose, confirm latent TB testing and hepatitis B evaluation when indicated, and verify the patient is not actively infected. After each injection, monitor for injection-site reactions and teach patients to report persistent fever, cough, weight loss, night sweats, shortness of breath, or signs of hepatitis. Escalate according to facility policy.
Major diagnostic safety note
Adalimumab carries a boxed warning for serious infections and malignancy. TNF blockade can reactivate tuberculosis and hepatitis B even after negative baseline screening. Nurses must not treat this as a simple injection appointment — infection assessment precedes every dose when symptoms are present.
- Scheduled injection during febrile illness or untreated active infection
- Positive latent TB without completed anti-TB therapy before first dose
- Hepatitis B carrier without monitoring plan — reactivation can be fatal per FDA label
- Live vaccine given concurrently or systemic fungal infection in endemic-area traveler
Document: TB/HBV screening status, infection assessment, hold/deferral reasons, dose and site, lot number, prescriber notification, and infection teaching.
What the test can and cannot tell you
Adalimumab therapy and screening can help support:
- Identification of latent TB before TNF blockade when screening tests are completed and reviewed
- Hepatitis B carrier detection in at-risk patients before immunosuppressive biologic therapy
- Clinical response tracking through symptom and functional assessment over time
- Early recognition of serious infection requiring drug hold and urgent workup
This therapy and screening cannot:
- Rule out active TB forever after one negative latent test — ongoing monitoring is required per FDA label
- Replace clinical judgment for infection — patients may need chest imaging or cultures when symptomatic
- Provide a universal blood level target — routine therapeutic drug monitoring is not standard
- Cure autoimmune disease — it modulates inflammation and requires long-term safety surveillance
Before the test — nursing safety check
Verify
Clarify before proceeding when:
- First dose planned but TB or HBV screening incomplete or not reviewed by prescriber
- Patient is febrile or has new cough, weight loss, night sweats, or dysuria
- Medication was frozen, expired, or outside labeled storage conditions
- Patient received a live vaccine recently or plans travel to endemic fungal region without prescriber review
- Injection site shows spreading erythema, warmth, or purulent drainage suggesting infection
- Concurrent abatacept, anakinra, or duplicate biologic ordered without specialist clarification
- Patient reports numbness, weakness, or vision changes suggesting demyelinating disease per label warnings
How to interpret the result clinically
Integrate screening tests, symptoms, vital signs, travel history, and concurrent immunosuppressants. A negative QuantiFERON at baseline does not override new pulmonary symptoms months later on adalimumab.
| Clinical context | Pair with screening/clinical data | Nursing focus |
|---|---|---|
| Before first dose | Negative latent TB; HBV serology reviewed | Confirm prescriber clearance; teach infection reporting |
| Stable on therapy | No fever; mild localized injection-site redness | Continue schedule; rotate sites; document tolerance |
| New fever on therapy | Tachycardia, cough, or hypoxia | Hold dose; escalate infection/TB workup per protocol |
| HBV carrier | Rising ALT/AST or jaundice | Stop adalimumab per label; notify prescriber urgently |
Practical bedside notes
| Bedside point | Nursing note |
|---|---|
| Negative TB test at start | Still monitor for active TB during therapy — label requires ongoing surveillance |
| Cold chain | Never freeze; record date removed from fridge if using 14-day room-temperature option |
| Site rotation | Thigh or abdomen; separate sites if two injections needed same day per label |
| Injection vs infection | Localized mild redness may be expected; spreading warmth/pus requires assessment |
| Live vaccines | Avoid during therapy; plan with prescriber before travel or pediatric catch-up |
| Biosimilars | Same infection principles apply — verify specific device instructions for each product |
Clinical practice integration and workflow
Diagnostic safety badge: High-risk biologic therapy — infection screening and symptom review required before each dose when clinically indicated.
Check-before-dose protocol
- Identity + correct biologic product and dose
- Screening status (TB/HBV) on file for new starts
- Active infection symptom screen and vital signs
- Storage integrity and expiration check
- Injection site plan, technique, and post-injection teaching
Critical teach-back questions
- “Can you tell me which infection symptoms should make you call the clinic before your next injection?”
- “How should you store your pen or syringe at home?”
- “Which types of vaccines should you check with your doctor before receiving?”
Care coordination: rheumatology, gastroenterology, dermatology, infectious diseases, pharmacy biologics team, primary care, and vaccination services.
Quick mental checklist
- Is latent TB screening complete and reviewed before a first dose?
- Does the patient have fever, cough, or other infection signs today?
- Is the biologic stored correctly and within expiration?
- Has the patient avoided live vaccines during therapy?
- Who must be notified if the dose is held for suspected serious infection?
Why Adalimumab is Ordered
Adalimumab is prescribed when autoimmune or inflammatory disease requires TNF blockade after specialist assessment. FDA-approved adult indications include moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis, with additional pediatric indications per label.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Rheumatoid arthritis (moderately to severely active) | Can TNF blockade reduce joint inflammation and slow structural damage? | Supports symptom control and function; nurses monitor infection risk and injection adherence. |
| Crohn’s disease or ulcerative colitis | Is intestinal inflammation severe enough to require biologic therapy? | Nurses track GI symptoms, infection signs, and vaccination status; dosing schedules vary by indication. |
| Plaque psoriasis or hidradenitis suppurativa | Is skin or HS disease moderate to severe despite other options? | Supports dermatology follow-up; teach injection technique and skin infection reporting. |
| Ankylosing spondylitis or psoriatic arthritis | Are axial or peripheral inflammatory symptoms active despite standard therapy? | Monitor mobility, pain trends, and infection cues during ongoing every-other-week or weekly regimens. |
Contraindications and Precautions
The FDA label lists no formal contraindications for adalimumab, but the boxed warning and warnings/precautions define high-risk scenarios. Nurses treat active infection, unaddressed latent TB, and live-vaccine timing as reasons to clarify or hold therapy with the prescriber.
- Active infection is present — FDA label states do not start adalimumab during an active infection
- Latent TB is positive and anti-TB treatment has not been started per specialist plan
- Patient has untreated active TB or systemic illness suggestive of opportunistic infection
- Hepatitis B carriers — monitor during and several months after therapy; stop drug if reactivation occurs per label
- Live vaccines should be avoided; bring pediatric patients up to date before starting when possible
- Heart failure, demyelinating disease history, cytopenias, and malignancy history require prescriber awareness
- Persistent fever, cough, weight loss, or night sweats suggesting TB or serious infection
- Signs of anaphylaxis or serious hypersensitivity during or after injection
- Jaundice, dark urine, or abdominal pain suggesting hepatitis B reactivation in at-risk patients
Patient Preparation
Preparation combines infection screening before initiation, safe cold-chain handling of the biologic, and subcutaneous injection readiness. Follow the specific product label, institutional biologic protocol, and prescriber orders.
Pre-test checksReview concurrent immunosuppressants (methotrexate, corticosteroids), abatacept, anakinra, and other biologics — combinations may increase serious infection risk per label. Do not independently hold or start medicines unless authorized by prescriber or protocol.
Subcutaneous Administration Workflow
Verify the Order and Patient Identity
Use two identifiers, verify adalimumab order (dose, frequency, indication), and confirm screening labs are reviewed by the prescriber before first dose.
Explain the Test and Obtain Consent
Explain the injection process, expected mild injection-site reactions, and symptoms requiring urgent reporting (fever, breathing difficulty, allergic signs).
Prepare Supplies and the Environment
Inspect prefilled pen, syringe, or vial for expiration, integrity, and proper storage history; do not use if frozen, expired, or discolored per label.
Prepare the Injection Site
Choose thigh or abdomen; rotate sites with each dose. Clean skin with alcohol and allow to dry. Do not inject into areas with psoriasis plaques, redness, or infection.
Administer Subcutaneously
Follow device-specific instructions for pen or syringe. Inject subcutaneously — not intravenously or intramuscularly. Proper training is required before patient or caregiver self-administration per FDA label.
Observe for Immediate Reactions
Monitor for anaphylaxis, urticaria, or bronchospasm after injection. Most injection-site reactions are mild (redness, itching, swelling) and may not require stopping therapy.
Safe Disposal and Storage Teaching
Dispose of sharps in approved container. Reinforce refrigeration requirements and 14-day room-temperature limit if applicable; record date removed from refrigerator on carton per label.
Schedule and Follow-Up
Confirm next dose date (commonly every other week for many adult indications). Ensure patient knows whom to contact for fever, infection symptoms, or missed doses.
Label, Transport, and Document
Document screening review, dose, site, lot number if available, tolerance, teaching provided, and any prescriber notifications.
Workflow at a Glance
Typical nursing workflow from screening to ongoing injections:
Results and Interpretation
Adalimumab therapy is monitored clinically rather than by a universal blood level. Nurses interpret screening tests, symptom response, infection cues, and laboratory trends ordered by the prescriber.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within reference interval | Negative latent TB screen before first dose (test type per institutional protocol) | No evidence of latent TB requiring treatment delay when prescriber clears initiation | Proceed with ordered start date after prescriber review; continue periodic TB surveillance per label |
| Borderline / near reference limit | Indeterminate TB test or unclear hepatitis B serology | May require repeat testing or infectious diseases consultation | Do not start adalimumab until prescriber clarifies; document hold reason |
| High / above reference interval | Positive latent TB test or active TB concern | Anti-TB therapy generally required before TNF blocker per FDA label | Hold biologic initiation; refer per protocol; monitor for active disease symptoms |
| Low / below reference interval | Not applicable — screening tests are interpreted as positive/negative/indeterminate rather than high/low drug levels | Not applicable for adalimumab drug level monitoring | Use clinical response and prescriber-directed labs rather than routine level checks |
Critical Safety Findings and Escalation
There is no standard laboratory critical value for adalimumab concentration. Critical nursing concerns are clinical: serious infection, TB reactivation, hepatitis B reactivation, and severe hypersensitivity.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Active or suspected tuberculosis during therapy | New cough, hemoptysis, fever, weight loss, night sweats, or positive TB workup | Stop adalimumab per prescriber/label guidance; escalate infection and TB workup per facility policy |
| Serious bacterial, fungal, or opportunistic infection | Sepsis signs, invasive fungal infection concern, or hospitalized infection per label warnings | Discontinue adalimumab if infection becomes serious per FDA label; activate urgent clinical response per protocol |
| Hepatitis B reactivation | Rising liver enzymes, jaundice, or HBV DNA reactivation in a carrier | Stop adalimumab and notify prescriber; antiviral therapy per specialist — per FDA label |
Stop routine injection workflow and escalate according to facility policy when the patient has active infection, anaphylaxis, serious systemic illness, TB symptoms, or hepatitis reactivation signs — or when screening is incomplete before a first dose.
Factors Affecting Results
Infection risk and injection outcomes may be affected by concurrent immunosuppression, travel history, vaccination timing, and technique.
- Mild injection-site erythema may mimic cellulitis but is often benign and local
- Upper respiratory symptoms may be viral rather than TB — still requires clinical assessment on TNF therapy
- Transient fatigue after injection may not indicate sepsis — interpret with vitals and trend
- Negative latent TB test does not eliminate active TB risk — continue monitoring during therapy per label
- Normal liver enzymes may not exclude HBV reactivation — carriers need ongoing surveillance when at risk
- Improved joint or GI symptoms do not mean infection risk has resolved
- Concurrent corticosteroids, methotrexate, or other biologics — increased infection risk
- Recent or planned live vaccines — avoid live vaccines with adalimumab per label
- Improper storage (freezing, prolonged room temperature) — may affect biologic integrity
Adalimumab suppresses inflammation but does not cure underlying autoimmune disease. It does not replace infection screening, cancer surveillance, or specialist follow-up. Effectiveness in ulcerative colitis has not been established in patients who lost response or were intolerant to other TNF blockers — per FDA label limitation.
Nursing Responsibilities
Nursing care spans pre-treatment screening, safe injection, infection education, and ongoing clinical monitoring between specialty visits.
Before the TestDocumentation
Documentation supports biologic safety audits, continuity between clinic visits, and medicolegal traceability for high-risk therapy.
“Adalimumab 40 mg subcutaneous injection given 0930 left anterior thigh. Latent TB QuantiFERON negative 05/2026 reviewed by rheumatology. HBV serology non-reactive. Patient afebrile; no active infection symptoms. Pen lot documented; sharp disposed. Tolerated injection; mild erythema at site. Infection/TB teaching reinforced; next dose in 2 weeks.”
- Screening results (TB, HBV) and prescriber clearance before first dose
- Dose, route, site, device, date, and lot number when available
- Patient tolerance and any injection-site or systemic reaction
- Education on infection symptoms and live-vaccine restrictions
- Hold or deferral reasons when infection suspected or screening incomplete
- Next appointment and prescriber notifications
Patient and Family Education
Use plain language while emphasizing that adalimumab lowers the immune response and requires prompt reporting of infection symptoms.
Adalimumab NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Adalimumab safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Adalimumab 40 mg subcutaneous — scheduled injection (rheumatoid arthritis)
- Indication: Moderately active RA; on methotrexate; monthly clinic injection visit
- Timing: Due today; last dose 14 days ago; latent TB test negative at initiation 6 months ago
- Related orders: Methotrexate weekly; CBC and liver function tests every 3 months; no current antibiotics
- Result: Today: afebrile at triage; screening labs from 6 months ago — QuantiFERON TB Gold negative
- Trend / prior value: Patient reports 5 days of low-grade fever, productive cough, and 2 kg weight loss
- Pending tests: Chest X-ray and repeat infectious workup not yet ordered
- Vital signs: T 38.1°C, HR 102/min, BP 118/72, RR 20, SpO₂ 94% on room air
- Symptoms: Productive cough, fatigue, night sweats; joints otherwise stable
- Focused assessment: Mild crackles at right base; injection site on prior thigh dose healed without redness
- Preparation notes: Pen removed from refrigerator 20 minutes ago; dose verified; patient asking why nurse is delaying injection
- Collection events: Patient received influenza (inactivated) vaccine 2 days ago without prescriber notification
- Teaching gaps / safety concerns: New systemic infection symptoms on TNF blocker; injection scheduled despite febrile illness
Answer key & rationale
Frequently Asked Questions
FAQ
Why is tuberculosis screening required before adalimumab?
TNF blockers increase the risk of tuberculosis reactivation and new TB infection, including disseminated disease. FDA labeling requires latent TB testing before initiation and treatment of latent TB before starting when positive, with ongoing monitoring during therapy.
Can adalimumab be given during a cold or fever?
Do not start adalimumab during an active infection. If infection develops during therapy, monitor carefully and stop adalimumab if the infection becomes serious — per FDA label. Clarify with the prescriber for mild illness before routine scheduled doses.
Are live vaccines safe with adalimumab?
No. FDA labeling states live vaccines should be avoided with adalimumab. Inactivated vaccines may be given per prescriber plan. Pediatric patients should be brought up to date with all vaccines before starting when possible.
Does adalimumab require routine blood level monitoring?
Routine therapeutic drug level monitoring is not standard for adalimumab in the reviewed FDA labeling. Prescribers may order CBC, liver function tests, or other labs per indication and institutional protocol — follow local orders.
What injection-site reactions are common?
Injection site reactions (redness, itching, pain, swelling) were the most common adverse reaction in clinical trials and occurred in about 20% of adalimumab-treated patients in placebo-controlled studies — usually mild and not requiring drug discontinuation per FDA label.
How should adalimumab be stored?
Refrigerate at 36°F to 46°F (2°C to 8°C); do not freeze. It may be stored at room temperature up to 77°F (25°C) for up to 14 days per FDA label. Protect from light in original carton until use.
When should nurses escalate care for patients on adalimumab?
Escalate according to facility policy for persistent fever, TB symptoms, serious or opportunistic infection, anaphylaxis, hepatitis reactivation signs, or new neurological symptoms. Stop therapy for serious infection or sepsis per FDA label.
References
References
-
U.S. Food and Drug Administration. HUMIRA (adalimumab) prescribing information. AbbVie Inc.; revised 2025.https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s424lbl.pdf
-
U.S. National Library of Medicine. Adalimumab. MedlinePlus; reviewed 2024.https://medlineplus.gov/druginfo/meds/a603010.html
-
U.S. National Library of Medicine. DailyMed — HUMIRA (adalimumab) kit. NLM.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d
-
Centers for Disease Control and Prevention. Tuberculosis (TB) — Health care workers. CDC.https://www.cdc.gov/tb/hcp/testing-diagnosis/index.html
-
Centers for Disease Control and Prevention. Hepatitis B Questions and Answers for Health Professionals. CDC.https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html
-
National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. NICE Guideline NG100.https://www.nice.org.uk/guidance/ng100
-
National Institute for Health and Care Excellence. Crohn’s disease: management. NICE Guideline NG129.https://www.nice.org.uk/guidance/ng129
-
American College of Rheumatology. Clinical Practice Guidelines. ACR.https://rheumatology.org/clinical-practice-guidelines
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Adalimumab.
Policies: Medical Review Process · Editorial Policy · Correction Policy